Back    Zoom +    Zoom -
<Research>Guotai Junan Initiates Rating Buy on SINO BIOPHARM w/ TP HKD10
Recommend
31
Positive
38
Negative
13
Guotai Junan has initiated coverage on SINO BIOPHARM (01177.HK) with a Buy rating and a target price of HKD10. Its 2025-27 EPS forecasts for the company were RMB0.293/ RMB0.259/ RMB0.283.

While investment sentiment in China's healthcare sector rebounded greatly over the past year, SINO BIOPHARM occupied a particularly advantageous position on the back of its enhanced innovation capabilities, its global layout, and improved capital market sentiment, Guotai Junan stressed.

Related NewsHSBC Research Ratings, TPs on Pharma, Biotech Stocks (Table)
As one of China's largest and most well-developed drug makers, SINO BIOPHARM's scale, financing capability, and commercial infrastructure enable it to acquire promising local biotech firms and accelerate the late-stage development and commercialization of assets.
AAStocks Financial News